This trial is active, not recruiting.

Condition hiv infections
Treatment t-1249
Phase phase 1/phase 2
Sponsor Trimeris
Trial identifier NCT00048217, T1249-105


Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Masking open label
Primary purpose treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Completion T1249-102; - Currently failing a T-20 containing regimen Exclusion Criteria: - Non-completion of T1249-102.

Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by Trimeris.